期刊文献+

阿奇霉素对慢性阻塞性肺疾病稳定期患者肺功能及细胞因子的影响 被引量:6

下载PDF
导出
摘要 目的探讨小剂量阿奇霉素对慢性阻塞性肺疾病(COPD)稳定期患者细胞因子和肺功能的影响。方法 COPD稳定期患者74例,随机分为对照组和治疗组,分别在治疗前、治疗8周结束后,评估临床症状,测定肺功能、动脉血气氧分压(PaO2)以及血清IL-8、IL-10、TNF-α水平。结果 8周治疗后,和对照组相比,治疗组患者CAT评分下降,PaO2升高,血清IL-8下降、IL-10升高,差异有统计学意义;FEV1、FEV1/FVC、FEV1%、TNF-α差异无统计学意义。结论小剂量阿奇霉素可能通过抑制气道炎症反应,使COPD稳定期患者IL-8下降,IL-10升高,改善临床症状和动脉血气氧分压,但对肺功能没有影响。
出处 《浙江实用医学》 2013年第6期388-390,共3页 Zhejiang Practical Medicine
基金 温州市医药卫生科研项目(2012B020)
  • 相关文献

参考文献9

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8227
  • 2Jones P W,Harding G,Berry P. Development and first validation of the COPD Assessment Test[J].{H}European Respiratory Journal,2009,(03):648.
  • 3姚婉珍.慢性阻塞性肺疾病[M]{H}北京:人民卫生出版社,200817.
  • 4蔡柏蔷.慢性阻塞性肺疾病发病机制的新进展[J].中华内科杂志,2000,39(3):204-206. 被引量:67
  • 5Horwitz D A,Zheng S G,Gray J D. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function 0f CD4+,CD25+ and CD8+ regulatory T cell subsets[J].{H}Leukoc Biol,2003,(04):471.
  • 6Wood L G,Gibsion P G,Garg M L. Biomarkers of lipid peroxidation,airway inflammation and asthma[J].{H}European Respiratory Journal,2003,(01):177.
  • 7樊涛,张宇,蒋洪丽,闵婕,王科,周维,毛兵.慢性阻塞性肺疾病患者肺组织丙二醛、白细胞介素8、肿瘤坏死因子α水平及吸烟的影响[J].中国呼吸与危重监护杂志,2012,11(3):218-222. 被引量:12
  • 8Giamarellos-Bourboulis E J. Maerolides beyond the conventional an-timicrobials:a class of potent immunomodulators[J].Int J Antimicrob A-gents,2008,(01):12.
  • 9Clement A,Tamalet A,Leroux E. Long term effects of azithromycin in patients with cystic fibrosis,A double blind,placebo controlled trial[J].{H}THORAX,2006,(10):895.

二级参考文献25

  • 1何娓娓,顾宇彤,王桂芳.氧化应激失衡在慢性阻塞性肺疾病患者发病及防治中的研究进展[J].中国呼吸与危重监护杂志,2011,10(2):200-201. 被引量:14
  • 2有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 3GOLD Executive Committee [ DB/OL]. Guidelines: Global Strategy for Diagnosis, Management, and Prevention of COPD (updated 2007). http://www. Goldcopd. org.
  • 4Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J, 2006,27:397-412.
  • 5Buist AS, Vollmer WM, Sullivan SD, et al. The burden of obstructive lung disease initiative (BOLD) : Rationale and Design. J COPD, 2005,2:277-283.
  • 6MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2005,2 : 50-60.
  • 7Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest, 1997, 112: 505-510.
  • 8Sato T, Sayama K, Sato Y, et al. Senescence marker protein-30 protects mice lungs from oxidative stress, aging, and smoking. Am J Respir Criti Care Med, 2006,174:530-537.
  • 9Macnee W. Oxidants/ antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp, 2001,234 : 169-188.
  • 10Macnee W, Donaldson K. Exacerbations of COPD: environmental mechanisms. Chest, 2000,117 (5 S2) :390S-397S.

共引文献8296

同被引文献36

  • 1欧立文,卢平.低剂量阿奇霉素对慢性阻塞性肺疾病稳定期患者气道中肿瘤坏死因子-α的影响及疗效[J].中国老年学杂志,2014,34(3):656-657. 被引量:26
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8227
  • 3Knobloch J, Wahl C, Feldmann M, et al. Resveratrol Attenuates the Release of Inflammatory Cytokines from Human Bronchial Smooth Muscle Ceils Exposed to Lipoteichoic Acid in Chronic Obstructive Pulmonary Disease[J]. Basic & Clinical Pharmacology & Toxicology, 2014, 114 (2) : 202-209.
  • 4Zhang L, Su Z, Zhang Z, et al. Effects of Azithromyein on Gene Expression Profiles of Proinflammatory and Anti-inflammatory Mediators in the Eyelid Margin and Conjunctiva of Patients With Meibomian Gland Disease[J]. Jama Ophthalmology, 2015,133( 10): 1329-1334.
  • 5殷少军.用最新指南指导老年COPD诊治[C]//全国老年医学进展学术会议暨江苏省牺医结合学会老年分会学术年会.江苏:江苏省中西医结合学会老年分会,2015.
  • 6Giamarellos-Bourboulis E J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators[J]. International Journal of Antimicrobial Agents, 2008, 31 (l) : 12-20.
  • 7Uzun S, Djamin R S, Kluytmans J, et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): Study protocol for a randomised controlled trial[J]. Trials, 2012, 13 ( 1 ) : 1-7.
  • 8Hodge S, Hodge G, Holmes M, et al. Increased CD8 T- cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin[J]. Respirology, 2015, 20 ( 1 ) : 95-100.
  • 9Woodruff P G, Chatila W, Connett J E, et al. Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial[J]. European Respiratory Journal, 2014, 43 (1) : 295-298.
  • 10Han M L K, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy[J]. American journal of respiratory and critical care medicine, 2014, 189 (12) : 1503-1508.

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部